- Home
- Media Center
- Press releases
- Medical technologies
Medical technologies
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
PRECEPT study demonstrated 15-month freedom from symptomatic persistent atrial fibrillation in 80.4 percent of patients who underwent cardiac ablation using THERMOCOOL SMARTTOUCH® SF Catheter1
Ethicon Launches VISTASEAL Fibrin Sealant (Human) to Manage Bleeding During Surgery
Next Generation Device Simplifies Setup and May Save Valuable Operating Room Time VISTASEAL is first innovation to emerge from Ethicon’s strategic partnership with Grifols, a pioneer in the plasma industry
Auris Health Announces Late-Breaking Results from First-in-Human Study of Monarch™ Platform
Data Presented at CHEST 2019 Demonstrates Efficacy of Monarch to Successfully Reach Nodules and Biopsy Tissue
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)
Stay informed with the latest results from the SPARTAN study, showcasing a significant 25% reduction in the risk of death for prostate cancer patients.
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease